RecruitingNCT05475015

3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension

Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study


Sponsor

Shengjing Hospital

Enrollment

150 participants

Start Date

Aug 16, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Interventions

DEVICE3D-MRE

All imaging studies were performed by using a 3.0-T MRI system ( GE Healthcare) with a phasedarray body coil.

DEVICEHVPG

HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.


Locations(1)

Shengjing Hospital

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05475015


Related Trials